How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,911 results for

Prostate Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

261. Accuracy of gallium-68 prostate-specific membrane antigen positron emission tomography for local staging of prostate cancer: a systematic review and meta-analysis

Accuracy of gallium-68 prostate-specific membrane antigen positron emission tomography for local staging of prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability (...) species); sex (stratified per sex); duration of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease

2019 PROSPERO

262. Quality indicators for the management of head and neck squamous cell carcinoma

and neck (DS-3) 60 5.1.4 FDG-PET(/CT) before treatment (DS-4) 62 5.2 QUALITY OF TREATMENT IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK 64 5.2.1 Single modality treatment in stage I-II (T-1) 64 5.2.2 Total laryngectomy in T4a laryngeal cancer (SX-1) 66 5.2.3 Timeliness postoperative radiotherapy (RT-1) 67 5.2.4 Primary chemoradiotherapy for locally-advanced non-metastatic disease (RT-2) 69 5.2.5 Neck imaging after primary (chemo)radiotherapy (LN-1) 71 5.2.6 Elective neck dissection in cN0M0 squamous (...) cancers. 9 About 91% of all head and neck cancers are squamous cell carcinomas, 2% are sarcomas and the other 7% are adenocarcinomas, melanomas and not well specified tumours. 10 KCE Report 305 Quality indicators for the management of HNSCC 23 Head & neck cancers occur preferentially in males. In 2016, there were 2 694 new diagnoses of head and neck cancer in Belgium, 2 005 in males and 689 in females. 11 In Belgium, head and neck cancer is the 4 th most frequent tumour in males (6% of all

2019 Belgian Health Care Knowledge Centre

263. Management of hepatocellular carcinoma

; recommendation strong). Imaging-based diagnosis Imaging is an essential part of hepatocellular carcinoma (HCC) diagnosis, contributing to primary liver tumour typing and HCC staging. Non-invasive imaging diagnosis of HCC in the set- ting of a cirrhotic liver was accepted in 2001, when dynamic imaging explorations demonstrated the typical diagnostic pat- tern 155 (updated in 2005 156 ). Imaging-based diagnosis relies on the peculiar vascular derangement occurring during hepatic carcinogenesis 157 (...) –surgicalfeasibilitymayvaryaccordingtothe liver volume and function-preservation principles summarised previously.However,studieshavecon?rmedthatpost-resection outcome decreases as tumour size increases. It is worth noting thatwhileHCCsbeyond5cmstillqualifyasanearlystageeligi- ble for LR – if technically feasible, according to Barcelona Clinic Liver Cancer (BCLC) classi?cation – the 5cm cut-off de?nes tumours trespassing into theintermediate-stage in other classi- ?cations 266 andalsode?nesthelimitinsizeforwhichanHCCis excluded from

2018 European Association for the Study of the Liver

264. The Oncentra Prostate v4.x for ultrasound-guided real-time HDR brachytherapy in men with localised prostate cancer

prostate cancer treated with high-dose-rate real-time brachytherapy. Study design A retrospective, single-centre, feasibility study. Setting Spain Inclusion/ exclusion criteria Inclusion criteria: proven adenocarcinoma of the prostate; clinical (MR imaging) stage T3a disease and without clinical or radiographic evidence of metastases Primary outcomes All outcomes were presented as mean figures. Prostate dose volume histograms Extracapsular extension (ECE) Maximal urethral and rectum dose The Oncentra (...) (clinical tumour stage 3a) who had real-time HDR brachytherapy. Real-time MRI/TRUS fusion can be done using the 'Fusion for all modalities' module of the Oncentra Prostate v4.x. The authors analysed men with intermediate- and high-risk prostate cancer who had a single HDR fraction of 15 Gy followed by EBRT at a dose of 37.5 Gy delivered in 15 fractions over 3 weeks. For each participant, 2 virtual treatment plans were developed based on the MRI/TRUS fusion images. These treatment plans were only

2014 National Institute for Health and Clinical Excellence - Advice

265. On the relationship between tumor structure and complexity of the spatial distribution of cancer cell nuclei: A fractal geometrical model of prostate carcinoma. (Abstract)

On the relationship between tumor structure and complexity of the spatial distribution of cancer cell nuclei: A fractal geometrical model of prostate carcinoma. A risk of the prostate cancer patient is defined by both the objective and subjective criteria, that is, PSA concentration, Gleason score, and pTNM-stage. The subjectivity of tumor grading influences the risk assessment owing to a large inter- and intra-observer variability. Pathologists propose a central prostate pathology review (...) as a remedy for this problem; yet, the review cannot eliminate the subjectivity from the diagnostic algorithm. The spatial distribution of cancer cell nuclei changes during tumor progression. It implies changes in complexity measured by the capacity dimension D0, the information dimension D1, and the correlation dimension D2.The cornerstone of the approach is a model of prostate carcinomas composed of the circular fractals CF(4), CF(6 + 0), and CF(6 + 1). This model is both geometrical and analytical

2014 Prostate

266. Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. (Abstract)

Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. Circulating tumour cells (CTCs) have been studied as biomarkers of a number of solid malignancies. Potential clinical applications for CTC analysis include early cancer detection, disease staging, monitoring for recurrence, prognostication, and to aid in the selection of therapy. In the field of urologic oncology, CTCs have been most widely studied as prognostic biomarkers of castration-resistant prostate cancer (...) . Additionally, emerging data support a role for CTCs to help identify which patients are most likely to respond to novel androgen-pathway targeted therapies, such as abiraterone and enzalutamide. CTCs have also been studied as predictive biomarkers of bladder cancer, in particular as a means to identify patients whose disease has been clinically understaged. Less is known regarding CTCs in kidney cancer; this has been attributed to the fact that a minority of renal tumours express EpCAM, the epithelial cell

2016 Nature reviews. Urology

267. Detection of circulating tumor cells in patients with esophagogastric or pancreatic adenocarcinoma using the CellSearch® system: An observational feasibility study Full Text available with Trip Pro

Detection of circulating tumor cells in patients with esophagogastric or pancreatic adenocarcinoma using the CellSearch® system: An observational feasibility study Circulating tumor cells (CTCs) in the blood of cancer patients have been demonstrated to be of prognostic value regarding metastasis and survival. The CellSearch® system has been certified for the detection of CTCs and as a prognostic tool in patients with metastatic breast, colon and prostate cancer. Few studies have evaluated (...) the detection of CTCs originating from esophagogastric or pancreatic cancer with the CellSearch® system. In the present small pilot study, a total of 16 patients with either esophagogastric (n=8) or pancreatic (n=8) adenocarcinomas at various disease stages were randomly screened and included. A total of 7.5 ml of blood was drawn from each patient and analyzed for CTCs using the CellSearch® device. CTCs could be detected in 1 out of 8 patients (12.5%) with esophagogastric and in 7 out of 8 patients (87.5

2016 Oncology letters

268. Endoscopic non-contact (side-firing) visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia (BPH)

/Consumer Issues Only targeted consultation was conducted for this application; however, no targeted feedback was received at the PASC stage. A letter of support was provided by the USANZ when the application was submitted to the Department. 8. Proposed intervention’s place in clinical management BPH is one of the most common diseases of the prostate, characterised by non-cancerous enlargement of the prostate causing the urethra to narrow and place pressure on the base of the bladder. Narrowing (...) (or severity) of lower urinary tract symptoms (LUTS) as indication for VLAP. Detection rate of incidental prostate cancer from tissue samples The true frequency (and significance) of incidental detection of prostate cancer is unknown. Fee ‘premium’ justification Justification for the fee premium is based on non-inferiority vs. TURP, longer procedure duration reduced length of stay. (NB: It is unknown whether lower MBS fee is the main or only reason for current preferential use of TURP over VLAP.) 2

2019 Medical Services Advisory Committee

269. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. Full Text available with Trip Pro

, and 81.3% had stage IV disease at the time of genomic analysis, with prostate, renal, pancreatic, breast, and colon cancer as the most common diagnoses. Of the 1040 patients, 182 (17.5%; 95% CI, 15.3%-19.9%) had clinically actionable mutations conferring cancer susceptibility, including 149 with moderate- to high-penetrance mutations; 101 patients tested (9.7%; 95% CI, 8.1%-11.7%) would not have had these mutations detected using clinical guidelines, including 65 with moderate- to high-penetrance (...) Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. Guidelines for cancer genetic testing based on family history may miss clinically actionable genetic changes with established implications for cancer screening or prevention.To determine the proportion and potential clinical implications of inherited variants detected using simultaneous sequencing of the tumor and normal tissue ("tumor

2017 JAMA

270. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers Full Text available with Trip Pro

Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers Osteopontin (OPN) is a secreted glycoprotein, that belongs to the non-structural extracellular matrix (ECM), and its over expression in human prostate cancer has been associated with disease progression, androgen independence and metastatic ability. Nevertheless, the pathophysiology of OPN in prostate tumorigenesis has never been studied. We crossed (...) TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice with OPN deficient (OPN-/-) mice and followed tumor onset and progression in these double mutants. Ultrasound examination detected the early onset of a rapidly growing, homogeneous and spherical tumor in about 60% of OPN-/- TRAMP mice. Such neoplasms seldom occurred in parental TRAMP mice otherwise prone to adenocarcinomas and were characterized for being androgen receptor negative, highly proliferative and endowed with neuroendocrine (NE

2015 Oncotarget

271. Comprehensive Evaluation of Prostate-Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. (Abstract)

patients with renal cell carcinoma were included in study with a median followup exceeding 10.0 years. Prostate specific membrane antigen expression on tumor vessels was detected by immunohistochemistry. Vascular expression of FOLH1 gene (prostate specific membrane antigen) mRNA was investigated in clear cell carcinoma and papillary renal cell carcinoma using TCGA (The Cancer Genome Atlas) data.Endothelial prostate specific membrane antigen protein expression was higher in clear cell than in papillary (...) and chromophobe renal cell carcinoma. Higher grade and stage, metastatic and lethal clear cell renal cell carcinoma showed higher prostate specific membrane antigen expression in tumor vessels. On univariate and multivariate analysis the intensity of positive vs negative endothelial prostate specific membrane antigen protein expression was significantly associated with overall survival. TCGA based analyses confirmed the prognostic role of vascular expression of FOLH1 mRNA. The analyses also supported

2017 Journal of Urology

272. Does the Prostate Health Index Depend on Tumor Volume?—A Study on 196 Patients after Radical Prostatectomy Full Text available with Trip Pro

Does the Prostate Health Index Depend on Tumor Volume?—A Study on 196 Patients after Radical Prostatectomy The Prostate Health Index (PHI) has been used increasingly in the context of prostate cancer (PCa) diagnostics since 2010. Previous studies have shown an association between PHI and a tumor volume of >0.5 cm³. The aim of this study was to investigate the correlation between PHI and tumor volume as well as the Gleason score. A total of 196 selected patients with prostate cancer treated (...) with radical prostatectomy at our institution were included in our study. The tumor volume was calculated and preoperative serum parameters total prostate-specific antigen (tPSA), free PSA (fPSA), [-2]proPSA, and PHI were evaluated. The association between the pathological findings such as Gleason score, pathological T-stage (pT stage), and tumor volume were evaluated. We further used logistic regression and Cox proportional hazard regression analyses for assessing the association between tumor volume

2017 International journal of molecular sciences

273. Modulation of cabozantinib efficacy by the prostate tumor microenvironment Full Text available with Trip Pro

Modulation of cabozantinib efficacy by the prostate tumor microenvironment The tumor microenvironment (TME) is increasingly recognized as the arbiter of metastatic progression and drug resistance in advanced prostate cancer (PCa). Cabozantinib is a potent tyrosine kinase inhibitor (TKI) with reported biological activity in the PCa epithelia, but failed to provide an overall survival benefit in phase 3 clinical trials. However, the promising biologic efficacy of the drug in early trials (...) impacted bone turnover, but not necessarily tumor expansion. Cabozantinib affected M1 macrophage polarization in mice. Analogously, circulating monocytes from PCa patients treated with cabozantinib, demonstrated a striking correlation of monocyte reprograming with therapeutic bone responsivity, to support patient selection at early stages of treatment. Thus, a re-evaluation of TKI-based therapeutic strategies in PCa can be considered for suitable patient populations based on TME responses.

2017 Oncotarget

274. Ormeloxifene suppresses prostate tumor growth and metastatic phenotypes via inhibition of oncogenic β-catenin signaling and EMT progression Full Text available with Trip Pro

Ormeloxifene suppresses prostate tumor growth and metastatic phenotypes via inhibition of oncogenic β-catenin signaling and EMT progression Ormeloxifene is a clinically approved selective estrogen receptor modulator, which has also shown excellent anticancer activity, thus it can be an ideal repurposing pharmacophore. Herein, we report therapeutic effects of ormeloxifene on prostate cancer and elucidate a novel molecular mechanism of its anticancer activity. Ormeloxifene treatment inhibited (...) proteins (inhibition of Mcl-1, cyclin D1, and CDK4 and induction of p21 and p27). In functional assays, ormeloxifene remarkably reduced tumorigenic, migratory, and invasive potential of prostate cancer cells. In addition, ormeloxifene treatment significantly (P < 0.01) regressed the prostate tumor growth in the xenograft mouse model while administered through intraperitoneal route (250 μg/mouse, three times a week). These molecular effects of ormeloxifene were also observed in excised tumor tissues

2017 Molecular cancer therapeutics

275. Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy Full Text available with Trip Pro

Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy The objective in this paper was to validate the prognostic performance of the American Joint Committee on Cancer (AJCC) 7th and 8th systems among prostate cancer patients treated with radical prostatectomy.The surveillance, epidemiology and end results (SEER) database (2006-2014) was accessed through the SEER*Stat program and AJCC 7th and 8th editions were (...) calculated utilizing T, N and M stages, histological grade group, as well as baseline prostatic-specific antigen (PSA). Cancer-specific and overall survival analyses according to 7th and 8th editions were conducted. Moreover, multivariate analysis was conducted through a Cox proportional hazard model.A total of 72,999 patients with prostate cancer were identified in the period from 2006 to 2014. Overall survival was assessed according to AJCC 7th and 8th staging systems. The test for trend for overall

2017 Therapeutic advances in urology

276. The Comparison and Estimation of the Prognostic Value of Lipid Profiles in Patients With Prostate Cancer Depends on Cancer Stage Advancement Full Text available with Trip Pro

The Comparison and Estimation of the Prognostic Value of Lipid Profiles in Patients With Prostate Cancer Depends on Cancer Stage Advancement Lipid profiles and prostate cancer have a controversial relationship, and the predictive ability of lipids in determining cancer risk estimation is still questionable. This study demonstrates a significance assessment of the plasma lipid profiles of subjects with prostate cancer. Locoregional subjects irradiated with external beam therapy were compared (...) to prostate cancer subjects with bone metastases. The histopathologic diagnosis of 103 subjects (71 locoregional [Group 1] and 32 palliative [Group 2]) were analyzed and compared using their blood samples, total cholesterol (CHL), triglycerides (TG), high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol. The HDL/CHL, LDL/CHL, and TG/HDL ratios were used for better fit and comparison. Subjects were grouped according to their cancer stages and assessed using statins

2017 American journal of men's health

277. Cancer-related hospitalisations and 'unknown' stage prostate cancer: a population-based record linkage study. Full Text available with Trip Pro

Cancer-related hospitalisations and 'unknown' stage prostate cancer: a population-based record linkage study. To identify reasons for prostate cancer stage being recorded as 'unknown' in Australia's largest population-based cancer registry.Prospective population-based cohort.New South Wales (NSW) is the most populous state in Australia, with almost one third of the total national population.NSW Cancer Registry (NSWCR) records for prostate cancer cases diagnosed in 2001-2009 were linked (...) to the NSW Admitted Patient Data Collection (APDC) for 2000-2010. All patients in this study had a minimum of 12 months follow-up in the hospital episode records after their date of diagnosis as recorded by the NSWCR.Incidence of 'unknown' stage prostate cancer and cancer-specific survival.Of 50 597 prostate cancer cases, 39.9% were recorded as having 'unknown' stage. Up to 4 months after diagnosis, 77.2% of cases without a hospital-reported cancer diagnosis were recorded as having 'unknown' stage. Among

2017 BMJ open

278. Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. (Abstract)

Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. We sought to independently validate the AJCC (American Joint Committee on Cancer) 8th edition prostate cancer staging classification, which includes the elimination of pT2 subcategories and the reclassification of patients with prostate specific antigen 20 ng/ml or greater and Gleason Grade Group 5 as stage groups III-A and III-C, respectively.We identified 13,839 men who (...) , 0.545 and 0.525, respectively). At the same time patients with 7th edition stage group II prostate cancer and prostate specific antigen 20 ng/ml or greater had significantly worse 15-year biochemical recurrence-free survival (42.2% vs 58.8%), metastasis-free survival (78.2% vs 88.8%) and cancer specific survival (88.0% vs 94.4%, all p <0.001) than patients with 7th edition stage group II prostate cancer and prostate specific antigen less than 20 ng/ml. However, patients with 7th edition stage group

2017 Journal of Urology

279. Trends in the use of radiation therapy for stage IIA prostate cancer from 2004 to 2013: a retrospective analysis using the National Cancer Database. (Abstract)

Trends in the use of radiation therapy for stage IIA prostate cancer from 2004 to 2013: a retrospective analysis using the National Cancer Database. Recent studies have shown a decrease in the overall use of radiation therapy in the treatment of prostate cancer over the past several decades, as well as a more conservative overall treatment approach. We aim to determine whether this trend continued from 2004 to 2013, and to determine whether there were changes in utilization for various types (...) of radiation.We conducted this retrospective study using the National Cancer Database. We identified 706 877 patients with sufficient treatment information diagnosed with stage IIA prostate cancer between 2004 and 2013. Logistic regression models were used to evaluate the yearly trend in radiation therapy utilization.There was a significant decline in the use of radiation therapy from 2004 to 2013, from 54.4% in 2004 to 34.5% in 2013 compared with all the other treatments. The use of external beam radiation

2017 Prostate cancer and prostatic diseases

280. High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation Full Text available with Trip Pro

High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation Ras homolog gene family, member A (RhoA) has been reported as essential to the invasion process and aggressiveness of numerous cancers. However, there are only sparse data on the expression and activity of RhoA in clinically localised prostate cancer. In numerous cancers, tumour cells at the invasive front demonstrate more aggressive behaviour in comparison (...) with the cells in the central regions. In the present study, the expression and activity of RhoA was evaluated in 34 paraffin-embedded and 20 frozen prostate tissue specimens obtained from 45 patients treated with radical prostatectomy for clinically localised cancer. The expression patterns of RhoA were assessed by immunohistochemical staining and western blotting. Additional comparisons were performed between the tumour centre, tumour front and distant peritumoural tissue. RhoA activity was assessed by G

2015 Oncology letters

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>